Hemostemix Inc.
HMTXF
$0.06
$0.00-4.40%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.17% | 199.79% | 61.43% | -28.74% | 11.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.93% | 197.06% | 99.71% | -29.19% | -8.65% |
| Operating Income | -31.93% | -197.06% | -99.71% | 29.19% | 8.65% |
| Income Before Tax | 41.40% | -153.79% | -85.81% | -20.23% | -78.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.40% | -153.79% | -85.81% | -20.23% | -78.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.40% | -153.79% | -85.81% | -20.23% | -78.93% |
| EBIT | -31.93% | -197.06% | -99.71% | 29.19% | 8.65% |
| EBITDA | -31.93% | -197.06% | -99.76% | 29.19% | 8.62% |
| EPS Basic | 65.91% | -135.00% | -54.90% | -13.04% | -69.23% |
| Normalized Basic EPS | 66.67% | -136.00% | 17.54% | -41.67% | -170.00% |
| EPS Diluted | 65.91% | -135.00% | -54.90% | -13.04% | -69.23% |
| Normalized Diluted EPS | 66.67% | -136.00% | 17.54% | -41.67% | -170.00% |
| Average Basic Shares Outstanding | 68.12% | 9.11% | 20.40% | 3.09% | 7.29% |
| Average Diluted Shares Outstanding | 68.12% | 9.11% | 20.40% | 3.09% | 7.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |